Castle Biosciences, Inc. (CSTL)
NASDAQ (NMS) NASDAQ (NMS) Primary 
Castle Biosciences, Inc. (CSTL) Tops Q3 Earnings and Revenue Estimates
Castle Biosciences, Inc. (CSTL) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of a loss of $0.06 per share. This compares to loss of $0.26 per share a year ago.
Castle Biosciences, Inc. (CSTL) Hit a 52 Week High, Can the Run Continue?
Castle Biosciences (CSTL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Here's Why Momentum in Castle Biosciences (CSTL) Should Keep going
Castle Biosciences (CSTL) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Castle Biosciences, Inc. (CSTL) is a Great Momentum Stock: Should You Buy?
Does Castle Biosciences, Inc. (CSTL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Castle Biosciences, Inc. (CSTL) Soars to 52-Week High, Time to Cash Out?
Castle Biosciences (CSTL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Strength Seen in Castle Biosciences (CSTL): Can Its 9.4% Jump Turn into More Strength?
Castle Biosciences (CSTL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Castle Biosciences (CSTL) Upgraded to Strong Buy: Here's What You Should Know
Castle Biosciences (CSTL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Castle Biosciences: Inflection Into Profitability
Castle Biosciences is a fast-growing molecular diagnostics company with a focus on prognostic tests for cancer and mental health patients. The company inflected into net income and operating profitability in Q2 2024, driving institutional and retail interest. CSTL faces risks from the loss of its DecisionDX-SCC business and general obsolescence in the cancer prognostic testing field.
Castle Biosciences, Inc. (CSTL) Q2 2024 Earnings Call Transcript
Castle Biosciences, Inc. (NASDAQ:CSTL ) Q2 2024 Earnings Conference Call August 5, 2024 4:30 PM ET Company Participants Camilla Zuckero - VP, IR & Corporate Affairs Derek Maetzold - Founder, President and CEO Frank Stokes - CFO Conference Call Participants Catherine Schulte - Baird Mason Carrico - Stephens Thomas Flaten - Lake Street Puneet Souda - Leerink Partners Kyle Mikson - Canaccord Genuity Sung Nam - Scotiabank Subbu Nambi - Guggenheim Mark Massaro - BTIG Operator Good afternoon, and welcome to Castle Biosciences Second Quarter 2024 Conference Call. As a remainder, today's call is being recorded.
Castle Biosciences, Inc. (CSTL) Q2 Earnings and Revenues Beat Estimates
Castle Biosciences, Inc. (CSTL) came out with quarterly earnings of $0.31 per share, beating the Zacks Consensus Estimate of a loss of $0.16 per share. This compares to loss of $0.70 per share a year ago.
Will Castle Biosciences, Inc. (CSTL) Report Negative Earnings Next Week? What You Should Know
Castle Biosciences (CSTL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
All You Need to Know About Castle Biosciences (CSTL) Rating Upgrade to Strong Buy
Castle Biosciences (CSTL) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
